Form 4 for EOG EOG Resources
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-02 · accession 0001127602-22-008104 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-03 | 2022-03-02 | EOG | Helms Lloyd W Jr | Pres, COO | F - Tax | $117.50 | -1,974 | 133.8K | -1% | -$231.9K |
| DM | 2022-03-03 | 2022-03-02 | EOG | Helms Lloyd W Jr | Pres, COO | D - Sale to Iss | $117.50 | -12.1K | 139.3K | -8% | -$1.42M |
| DM | 2022-03-03 | 2022-03-02 | EOG | Helms Lloyd W Jr | Pres, COO | M - OptEx | $72.68 | +19.5K | 140.7K | +16% | +$1.42M |
| DM | 2022-03-03 | 2022-03-02 | EOG | Helms Lloyd W Jr | Pres, COO | M - OptEx | $0.00 | -19.5K | 12.1K | -62% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-02 | F | D | 786 | $117.50 | 136,216.86 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-02 | D | D | 5,721 | $117.50 | 137,002.86 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-02 | D | D | 2,427 | $117.50 | 133,503.86 | D | — | — | |
| 4 | Common | Common Stock | 2022-03-02 | F | D | 140 | $117.50 | 133,363.86 | D | — | — | |
| 5 | Common | Common Stock | 2022-03-02 | M | A | 8,951 | $75.09 | 142,723.86 | D | — | — | |
| 6 | Common | Common Stock | 2022-03-02 | M | A | 3,000 | $95.05 | 135,930.86 | D | — | — | |
| 7 | Common | Common Stock | 2022-03-02 | F | D | 916 | $117.50 | 138,385.86 | D | — | — | |
| 8 | Common | Common Stock | 2022-03-02 | M | A | 3,000 | $96.29 | 136,363.86 | D | — | — | |
| 9 | Common | Common Stock | 2022-03-02 | D | D | 2,459 | $117.50 | 133,904.86 | D | — | — | |
| 10 | Common | Common Stock | 2022-03-02 | F | D | 132 | $117.50 | 133,772.86 | D | — | — | |
| 11 | Common | Common Stock | 2022-03-02 | M | A | 4,529 | $37.44 | 140,745.86 | D | — | — | |
| 12 | Common | Common Stock | 2022-03-02 | D | D | 1,444 | $117.50 | 139,301.86 | D | — | — | |
| 13 | Derivative | Stock Appreciation Rights | 2022-03-02 | M | D | 3,000 | $0.00 | 9,825 | D | $95.05 · 2017-09-29 to 2023-09-29 | 3,000 Common Stock | (F1) The SARs granted became exercisable in 25% increments beginning one year from the September 29, 2016 date of grant and on each of the next three grant date anniversaries. The SARs granted became fully exercisable on September 29, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 14 | Derivative | Stock Appreciation Rights | 2022-03-02 | M | D | 3,000 | $0.00 | 10,950 | D | $96.29 · 2018-09-25 to 2024-09-25 | 3,000 Common Stock | (F2) The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 25, 2017 date of grant. The SARs granted became fully exercisable on September 25, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 15 | Derivative | Stock Appreciation Rights | 2022-03-02 | M | D | 8,951 | $0.00 | 6,157 | D | $75.09 · 2020-09-26 to 2026-09-26 | 8,951 Common Stock | (F3) The SARs granted become exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 26, 2019 date of grant. The SARs granted will become fully exercisable on September 26, 2022. This exercise did not involve any open-market sale of the Issuer's Common Stock. |
| 16 | Derivative | Stock Appreciation Rights | 2022-03-02 | M | D | 4,529 | $0.00 | 12,079 | D | $37.44 · 2021-09-28 to 2027-09-28 | 4,529 Common Stock | (F4) The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 28, 2020 date of grant. The SARs granted will become fully exercisable on September 28, 2023. This exercise did not involve any open-market sale of the Issuer's Common Stock. |